KR850004273A - 안정성이 증대된 재조합 감마 인터페론 및 그의 제조방법 - Google Patents

안정성이 증대된 재조합 감마 인터페론 및 그의 제조방법 Download PDF

Info

Publication number
KR850004273A
KR850004273A KR1019840007908A KR840007908A KR850004273A KR 850004273 A KR850004273 A KR 850004273A KR 1019840007908 A KR1019840007908 A KR 1019840007908A KR 840007908 A KR840007908 A KR 840007908A KR 850004273 A KR850004273 A KR 850004273A
Authority
KR
South Korea
Prior art keywords
amino acid
composition
acid sequence
polypeptide
expression carrier
Prior art date
Application number
KR1019840007908A
Other languages
English (en)
Other versions
KR940008978B1 (ko
Inventor
윌리암 그레이 패트릭
Original Assignee
월터 에이취. 드레거
제넨테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27072811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850004273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 월터 에이취. 드레거, 제넨테크 인코포레이티드 filed Critical 월터 에이취. 드레거
Publication of KR850004273A publication Critical patent/KR850004273A/ko
Application granted granted Critical
Publication of KR940008978B1 publication Critical patent/KR940008978B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

안정성이 증대된 재조합 감마 인터페론 및 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (50)

  1. a) N-말단에서 신장하는 하기의 아미노산 서열로 되는 제조합 감마 인터페론 폴리펩티드 :
    (상기 식에서, X는 메티오닌 잔기 또는 수소이고, Y는 글루타민 잔기이거나, X가 수소인 경우에는 글루타민 또는 피로글루타메이트 잔기임) b) 상기의 것과 동일한 특성을 갖는 a)의 감마 임터페론 폴리펩티드의 변이종을 포함하는 약리적 투여에 적합한 조성물.
  2. 제1항에 있어서, X가 메티오닌인 조성물.
  3. 제2항에 있어서, 상기 폴리펩티드가 X를 건너서 신장하는 126±n아미노산을 가지고n가 0또는 1-17의 정수인 조성물.
  4. 제3항에 있어서,n아미노산이,
  5. 제3항에 있엇, 폴리펩티드가 아미노산 143이 없거나 또는 Z가 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 또는 142인 아미노산 서열에서 아미노산 143까지가 없는 폴리티드의 유세체로된 군에서 선택되는 조성물.
  6. 제5항에 있어서, Z가 아미노산 127인 조성물.
  7. 제5항에 있어서, Z가 아미노산 128인 조성물.
  8. 제5항에 있어서, Z가 아미노산 129인 조성물.
  9. 제5항에 있어서, Z가 아미노산 130인 조성물.
  10. 제5항에 있어서, Z가 아미노산 131인 조성물.
  11. 제5항에 있어서, Z가 아미노산 132인 조성물.
  12. 제5항에 있어서, Z가 아미노산 133인 조성물.
  13. 제5항에 있어서, Z가 아미노산 134인 조성물.
  14. 제5항에 있어서, Z가 아미노산 135인 조성물.
  15. 제5항에 있어서, Z가 아미노산 136인 조성물.
  16. 제5항에 있어서, Z가 아미노산 137인 조성물.
  17. 제5항에 있어서, Z가 아미노산 138인 조성물.
  18. 제5항에 있어서, Z가 아미노산 139인 조성물.
  19. 제5항에 있어서, Z가 아미노산 140인 조성물.
  20. 제5항에 있어서, Z가 아미노산 141인 조성물.
  21. 제5항에 있어서, Z가 아미노산 142인 조성물.
  22. 제5항에 있어서, 아미노산 143만이 없는 조성물.
  23. 폴리펩틱드가 세포 병리 저해 마이크로타이터 분석에 있어서, 하기 아미노산 서열을 갖는 제조합 감마 인터페론의 활성과 거의 동링한 활성을 나타내는 제 1-22항 중 어느 하나에 따른 조성물.
    상기 식에서, X는 수소이고, A는 CYS-TYR-CYS임
  24. 세포병리 저해 마이크로타이터 분서에 있어서, 다음과 같은 아미노산 서열을 갖는 제조합 감마 인터페론의 활성에 거의 2배 이상의 활성을 나타내는 제1-22항 중 어느하나에 따른 조성물.
    상기 식에서 X는 수소이고, A는 CYS-TYR-CYS임.
  25. 형절변이 미생물 또는 세포 배양체에서, N-말단에서 신장하는 하기의 아미노산 서열로 되는 폴리 펩티드를 표현시킬 수 있는 복제성 표현 운반체.
  26. 제25항에 있어서, X가 메티오닌인 표현 운반체.
  27. 제26항에 있어서, 상기 폴리펩티드가 X를 건너서 신장하는 126+n아미노산을 갖고,n가 0 또는 1-17의 정수인 표현 운반체.
  28. 제27항에 있어서,n아미노산이
  29. 아미노산 129가 없거나 또는 Z가 아미노산 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 또는 142인 아미노산 서열 Z에서 아미노산 143까지가 없는 제28항에 열거한 풀리펩티드의 유사체로 되는 군에서 선택된 폴리펩티드를 표현시킬 수 있는 표현 운반체.
  30. 미생물에 사용하기 위한 제25-29항중 어느 하나에 따른 표현 운반체.
  31. 세균에 사용하기 위한 제25-29항중 어느 하나에 따른 표현 운반체.
  32. 상기 폴리펩티드의 표현이 어떠한 관련 신호 펩티드의 형성을 수반하지 않는 제 25-29항중 어느 하나에 따른 표현 운반체.
  33. 제25-29항중 어느 하나의 복재성 표현 운반체로 형질변이된 숙주 세포로 되는 형질변이 세포.
  34. 제52항중 어느 하나에 따른 미생물용 복제성 표현 운반체로 형질변이된 숙주 미생물로 되는 형질변이 미생물
  35. 제25-29항중 어느 하나에 따른 세균용 복제성 표현 운반체로 형질변이된 숙주 세균으로 되는 형질 변이 박테륨속.
  36. 암호 스트랜드가 하기 아미노산 서열로 되는 폴리펩티드를 암호화시키고, 상기 폴리펩티드의 N-말단에서 신장되는 암호 스트랜드 및 보충 스트랜드로 되는 이중 스트랜드 DNA.
  37. 제36항에 있어서, 상기 폴리펩티드가 초기에 암호화된 메티오닌 잔기를 건너서 신장하는 126+n아미노산(n은 0 또는 1-17의 정수임)을 갖는 이중 스트랜드 DNA.
  38. 제37항에 있어서, n아미노산이
  39. 암호 스트랜드가 아미노산 143이 없거나, 또는 Y가 아미노산 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 또는 142인 아미노산 서열 Y에서 143까지가 없는 제38항에서 열거한 폴리펩티드의 유사체로부터 선택된 폴리펩티드를 암호화시키는 암호 스트랜드와 보충스트랜드로되는 이중 스트랜드 DNA.
  40. 천연 인체 감마 인터페론의 특징적 특성을 나타내고, 적어도 제1항에 기재된 아미노산 서열을 함유하는 폴리펩티드.
  41. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이
  42. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이
  43. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이
  44. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이
  45. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이
    상기 식에서, Z는 수소,
  46. 제40항에 있어서, 아미노산 서열이 126 위치를 건너서 신장되고 이 아미노산 서열이로 되는 폴리펩티드.
    상기 식에서, Z는 수소,
  47. 제41항 또는 제42항의 폴리펩티드의 혼합물로 되는 조성물.
  48. 제47항에 있어서, 제41항의 폴리펩티드의 약 97Δ보가 큰 조성물.
  49. 제47항에 있어서, 제41항의 폴리펩티드의 약 97Δ보가 큰 조성물.
  50. 제1항에 있어서, 약리허용량의 인체 혈청 알부민으로 되는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840007908A 1983-12-16 1984-12-13 안정성이 증대된 재조합 감마 인터페론 및 그의 제조 방법 KR940008978B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56200983A 1983-12-16 1983-12-16
US6/562,009 1983-12-16
US06/562,009 1983-12-16
US06/584,217 1984-02-27
US6/584,217 1984-02-27
US06/584,217 US4855238A (en) 1983-12-16 1984-02-27 Recombinant gamma interferons having enhanced stability and methods therefor

Publications (2)

Publication Number Publication Date
KR850004273A true KR850004273A (ko) 1985-07-11
KR940008978B1 KR940008978B1 (ko) 1994-09-28

Family

ID=27072811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840007908A KR940008978B1 (ko) 1983-12-16 1984-12-13 안정성이 증대된 재조합 감마 인터페론 및 그의 제조 방법

Country Status (23)

Country Link
US (4) US4855238A (ko)
EP (1) EP0146354B2 (ko)
JP (6) JPH0789935B2 (ko)
KR (1) KR940008978B1 (ko)
AT (1) ATE135405T1 (ko)
AU (1) AU597872B2 (ko)
CA (1) CA1341573C (ko)
CY (1) CY1945A (ko)
DE (1) DE3486424T3 (ko)
DK (1) DK166832B1 (ko)
ES (1) ES8801553A1 (ko)
FI (1) FI91884C (ko)
GR (1) GR82468B (ko)
HK (1) HK175996A (ko)
HU (1) HU202278B (ko)
IE (1) IE72494B1 (ko)
IL (1) IL73803A (ko)
LV (1) LV11633B (ko)
MY (1) MY102899A (ko)
NO (1) NO178789C (ko)
OA (1) OA07902A (ko)
PH (1) PH24790A (ko)
PT (1) PT79691A (ko)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JPS60172999A (ja) * 1983-12-20 1985-09-06 Suntory Ltd 新規な塩基性ポリペプチドおよびその製造法
US4758656A (en) * 1983-12-26 1988-07-19 Kyowa Hakko Kogyo Co., Ltd. Novel human interferon-gamma polypeptide derivative
DE3582542D1 (de) * 1984-03-16 1991-05-23 Biogen Nv Verfahren zur expressionsverbesserung und mittel hierfuer.
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
IE58766B1 (en) * 1985-04-30 1993-11-03 Takeda Chemical Industries Ltd Production of protein
DE3532134A1 (de) * 1985-09-10 1987-03-12 Basf Ag Verfahren zur herstellung von proteinen bestimmter n-terminaler struktur mit hilfe von prokaryonten
DE3536939A1 (de) * 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
EP0275300B1 (en) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Recombinant vaccine
GB8619725D0 (en) * 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) * 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
DE3730331A1 (de) * 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
AT393690B (de) * 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
BG52073B2 (en) * 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
ATE112686T1 (de) * 1990-08-31 1994-10-15 Schering Corp Verwendungsmethoden von humanem gammainterferon 4-134.
DE4036856C1 (ko) * 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
CA2165666A1 (en) * 1993-07-01 1995-01-12 Hugh George Culture medium for recombinant yeasts
TW249202B (ko) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6187304B1 (en) 1998-04-02 2001-02-13 Genentech, Inc. Effects of IFN-γ on cardiac hypertrophy
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
RU2140285C1 (ru) 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
JP2003507006A (ja) * 1999-05-20 2003-02-25 サイオス，インコーポレーテッド 血管内皮増殖因子改変体
EP1183357A2 (en) * 1999-05-20 2002-03-06 Scios Inc. Vascular endothelial growth factor dimers
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
DE60129432T2 (de) * 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
KR20040007413A (ko) * 2000-11-03 2004-01-24 바이오메디신즈 인코포레이티드 단기 및 장기 약물 약량측정 방법
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
IL161630A0 (en) * 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
EP1450839A4 (en) * 2001-11-06 2009-06-24 Serono Lab METHOD OF TREATING BREAST CANCER THAT MEETS OESTROGENES
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
EP1461067A1 (en) * 2001-12-07 2004-09-29 Intermune, Inc. Compositions and method for treating hepatitis virus infection
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
US7524931B2 (en) * 2002-07-03 2009-04-28 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
TWI375679B (en) 2003-10-14 2012-11-01 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2006141263A (ja) * 2004-11-18 2006-06-08 Kyoto Univ （ｒ）−ヒドロキシニトリルリアーゼの製造方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR20080019606A (ko) * 2005-05-04 2008-03-04 나우틸루스 바이오텍 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8243103B2 (en) * 2009-05-29 2012-08-14 Exelis, Inc. Laser aiming spot distinguishing methods and apparatus
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
RU2575598C9 (ru) * 2010-02-01 2016-04-27 Дигна Байотек, С.Л. Способ получения белка альфа5-интерферона
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US11672877B2 (en) 2017-08-23 2023-06-13 Wayne State University In vivo immunoimaging of interferon-gamma
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
BR112022018615A2 (pt) 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
KR20230012471A (ko) 2020-03-30 2023-01-26 트리젤 엘티디. 암 치료용 조성물 및 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
NL7404590A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het reactiveren van interferon.
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4311639A (en) * 1980-07-25 1982-01-19 E. I. Du Pont De Nemours And Company Immunogenic interferon peptides
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4382027A (en) * 1981-08-18 1983-05-03 Meloy Laboratories, Inc. Purification of human immune interferon
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
IL69851A0 (en) * 1982-09-30 1983-12-30 Japan Found Cancer Novel dna and recombinant plasmid containing the same
WO1984002129A1 (en) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
JPS59169494A (ja) * 1983-03-17 1984-09-25 Takeda Chem Ind Ltd 新規組み換えｄｎａおよびその用途
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
JP2653061B2 (ja) 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法

Also Published As

Publication number Publication date
HU202278B (en) 1991-02-28
AU597872B2 (en) 1990-06-14
CA1341573C (en) 2008-05-13
LV11633B (en) 1997-08-20
CY1945A (en) 1984-12-14
PH24790A (en) 1990-10-30
OA07902A (en) 1986-11-20
AU3663584A (en) 1985-06-20
JPH0789935B2 (ja) 1995-10-04
FI91884B (fi) 1994-05-13
DE3486424T3 (de) 2002-06-06
JPS60202899A (ja) 1985-10-14
JP2545206B2 (ja) 1996-10-16
NO845042L (no) 1985-06-17
JPH08151399A (ja) 1996-06-11
EP0146354B2 (en) 2001-10-24
DK166832B1 (da) 1993-07-19
LV11633A (lv) 1996-12-20
IL73803A (en) 1997-09-30
NO178789B (no) 1996-02-26
DE3486424D1 (de) 1996-04-18
DK600984A (da) 1985-08-22
DK600984D0 (da) 1984-12-14
JPH0794477B2 (ja) 1995-10-11
JPH0919295A (ja) 1997-01-21
EP0146354A2 (en) 1985-06-26
IL73803A0 (en) 1985-03-31
ATE135405T1 (de) 1996-03-15
IE72494B1 (en) 1997-04-23
JPH07173196A (ja) 1995-07-11
IE843203L (en) 1985-06-16
ES8801553A1 (es) 1988-02-16
US5574137A (en) 1996-11-12
US5595888A (en) 1997-01-21
FI844934A0 (fi) 1984-12-13
HUT36187A (en) 1985-08-28
MY102899A (en) 1993-03-31
US4855238A (en) 1989-08-08
JP2580491B2 (ja) 1997-02-12
PT79691A (en) 1985-01-01
EP0146354A3 (en) 1986-03-19
JPH03201979A (ja) 1991-09-03
HK175996A (en) 1996-09-27
KR940008978B1 (ko) 1994-09-28
GR82468B (en) 1985-03-27
FI844934L (fi) 1985-06-17
JPH10210985A (ja) 1998-08-11
JP2719128B2 (ja) 1998-02-25
EP0146354B1 (en) 1996-03-13
ES538620A0 (es) 1988-02-16
US6497871B1 (en) 2002-12-24
NO178789C (no) 1996-06-05
JP2886145B2 (ja) 1999-04-26
FI91884C (fi) 1994-08-25
DE3486424T2 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
KR850004273A (ko) 안정성이 증대된 재조합 감마 인터페론 및 그의 제조방법
DE3583824D1 (de) Vorlaeufer des insulins, verfahren zu seiner herstellung und verfahren zur herstellung von humaninsulin aus solchen vorlaeufern des insulins.
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
KR830007825A (ko) 혼성의 인간 백혈구 인터페론
DE59504181D1 (de) Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
BR9807618A (pt) Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa.
ATE123949T1 (de) B-ketten-analoge des von blutplättchen abstammenden wachstumsfaktors und verfahren zu deren homogener herstellung.
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
KR920004419A (ko) 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
FI893833A0 (fi) Rekombinant aktivator foer naturliga doedarceller.
DE69131426D1 (de) Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
KR860002526A (ko) 단백질의 상호 분리 방법
KR920012440A (ko) 인간 인터류킨-5 수용체
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
KR850001287A (ko) 폴리펩타이드의 제조방법
AR013618A1 (es) Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferon
KR860000072A (ko) 임균 예방 백신의 제조방법
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
KR910016923A (ko) 트롬빈 결합성 물질의 제조법
ATE254179T1 (de) Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen
KR910007963A (ko) pST의 일부분에 대응하는 아미노산 서열을 갖는 펩티드, 그에 대한 항체 및 pST 활성에 효력을 더하는 방법
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
KR840007567A (ko) 펩티드의 제조방법
KR850700041A (ko) 티-세포 증식인자

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

J222 Remand (patent court)

Free format text: REMAND (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040924

Year of fee payment: 11

EXPY Expiration of term